Education
About Us
Working with TipRanks
Follow Us
Avantor Inc (AVTR)
NYSE:AVTR
AVTR Analyst Ratings
Moderate Buy
9 Buy
9 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AVTR Stock 12 Month Forecast
Average Price Target
$14.94
▲(12.33% Upside)
| Highest Price Target$30.00 | Average Price Target$14.94 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$13.5→$14
Hold
5.26%
Upside
Reiterated
08/23/25
Wells Fargo
$19→$16
Buy
20.30%
Upside
Reiterated
08/04/25
UBS
$14→$13
Hold
-2.26%
Downside
Reiterated
08/04/25
Robert W. Baird
$18→$15
Buy
12.78%
Upside
Reiterated
08/04/25
Citi
$14→$13
Hold
-2.26%
Downside
Reiterated
08/04/25
J.P. Morgan
$14
Buy
5.26%
Upside
Reiterated
08/04/25
Bernstein
$15→$13
Hold
-2.26%
Downside
Reiterated
08/04/25
Evercore ISI
$18→$16
Buy
20.30%
Upside
Reiterated
08/04/25
Another Guide cut was a tough pill to swallow…but stage is now well set for new CEO
Morgan Stanley
$15→$12
Hold
-9.77%
Downside
Reiterated
08/04/25
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)We decrease our PT to $12 from $15, using a target EV/26E EBITDA multiple of ~10x, a discount to Core Tools peers, which we view as justified in light of slower sales growth and lower EBITDA margins. Key takes from the call: 1. Although Lab Solutions revenue was in line with expectations, the Company continues to face high levels of competitive intensity, driven by the challenging funding and policy-related environment. Mgmt noted that this headwind is most pronounced among large biopharma accounts. The Company is implementing several actions in Lab Solutions to protect and grow market share, including leveraging pricing as a tool. The recent strategic initiatives have negatively impacted segment margins in 2Q, and are expected to continue pressuring margins in the near future.
William Blair
―
Hold
―
Assigned
08/04/25
Stifel Nicolaus
$14→$12
Hold
-9.77%
Downside
Reiterated
08/04/25
Raymond James
$14
Buy
5.26%
Upside
Reiterated
08/04/25
Barclays
$15→$13
Buy
-2.26%
Downside
Reiterated
08/04/25
TD Cowen
$15.5→$13
Hold
-2.26%
Downside
Reiterated
08/01/25
Jefferies
$12
Hold
-9.77%
Downside
Downgraded
08/01/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$13.5→$14
Hold
5.26%
Upside
Reiterated
08/23/25
Wells Fargo
$19→$16
Buy
20.30%
Upside
Reiterated
08/04/25
UBS
$14→$13
Hold
-2.26%
Downside
Reiterated
08/04/25
Robert W. Baird
$18→$15
Buy
12.78%
Upside
Reiterated
08/04/25
Citi
$14→$13
Hold
-2.26%
Downside
Reiterated
08/04/25
J.P. Morgan
$14
Buy
5.26%
Upside
Reiterated
08/04/25
Bernstein
$15→$13
Hold
-2.26%
Downside
Reiterated
08/04/25
Evercore ISI
$18→$16
Buy
20.30%
Upside
Reiterated
08/04/25
Another Guide cut was a tough pill to swallow…but stage is now well set for new CEO
Morgan Stanley
$15→$12
Hold
-9.77%
Downside
Reiterated
08/04/25
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)We decrease our PT to $12 from $15, using a target EV/26E EBITDA multiple of ~10x, a discount to Core Tools peers, which we view as justified in light of slower sales growth and lower EBITDA margins. Key takes from the call: 1. Although Lab Solutions revenue was in line with expectations, the Company continues to face high levels of competitive intensity, driven by the challenging funding and policy-related environment. Mgmt noted that this headwind is most pronounced among large biopharma accounts. The Company is implementing several actions in Lab Solutions to protect and grow market share, including leveraging pricing as a tool. The recent strategic initiatives have negatively impacted segment margins in 2Q, and are expected to continue pressuring margins in the near future.
William Blair
―
Hold
―
Assigned
08/04/25
Stifel Nicolaus
$14→$12
Hold
-9.77%
Downside
Reiterated
08/04/25
Raymond James
$14
Buy
5.26%
Upside
Reiterated
08/04/25
Barclays
$15→$13
Buy
-2.26%
Downside
Reiterated
08/04/25
TD Cowen
$15.5→$13
Hold
-2.26%
Downside
Reiterated
08/01/25
Jefferies
$12
Hold
-9.77%
Downside
Downgraded
08/01/25
Best Analysts Covering Avantor
1 Month
xxx
Success Rate
10/19 ratings generated profit
Average Return
-0.16%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.63% of your transactions generating a profit, with an average return of -0.16% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
Average Return
-0.90%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of -0.90% per trade.
1 Year
Success Rate
7/15 ratings generated profit
Average Return
-10.05%
reiterated a buy rating last month
Copying Michael Ryskin's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -10.05% per trade.
2 Years
xxx
Success Rate
3/23 ratings generated profit
Average Return
-25.00%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 13.04% of your transactions generating a profit, with an average return of -25.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AVTR Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
5
4
6
2
2
Buy
21
14
16
10
15
Hold
11
11
11
12
22
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
29
33
24
39
Each month's total comprises the sum of three months' worth of ratings.
AVTR Financial Forecast
AVTR Stock Forecast FAQ
What is AVTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Avantor Inc’s 12-month average price target is 14.94.
What is AVTR’s upside potential, based on the analysts’ average price target?
Avantor Inc has 12.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AVTR a Buy, Sell or Hold?
Avantor Inc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 9 hold ratings and 0 sell ratings.
What is Avantor Inc’s price target?
The average price target for Avantor Inc is 14.94. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $12.00. The average price target represents 12.33% Increase from the current price of $13.3.
The highest analyst price target is $30.00 ,the lowest forecast is $12.00. The average price target represents 12.33% Increase from the current price of $13.3.
What do analysts say about Avantor Inc?
Avantor Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of AVTR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.